生物催化
生化工程
风险分析(工程)
生物过程
生物技术
药物发现
计算机科学
设计质量
质量(理念)
监管科学
纳米技术
管理科学
化学
工程类
业务
生物
生物信息学
运营管理
材料科学
有机化学
认识论
催化作用
化学工程
离子液体
下游(制造业)
哲学
生态学
作者
Andrew S. Wells,John W. Wong,Peter C. Michels,David A. Entwistle,Keith R. Fandrick,Gregory L. Finch,Animesh Goswami,Heewon Lee,Stefan Mix,Thomas S. Moody,Long Pang,Robert K. Sato,Nicholas J. Turner,Timothy Watson
标识
DOI:10.1021/acs.oprd.5b00369
摘要
Biocatalysis is essentially the use of enzymes to perform chemical transformations on organic compounds and has been exploited for applications in various industries including food, fine chemicals, agrochemicals, and pharmaceuticals. Due to their selectivity and ability to operate under mild conditions, enzymes offer clear advantages for efficient sustainable manufacturing processes. Rapid development of enabling technologies including gene mining, molecular biology, biocatalyst evolution, and bioprocess engineering, has created opportunities to use biocatalysis more broadly for the manufacture of small molecule intermediates and APIs (active pharmaceutical ingredients). To facilitate the adoption of biocatalysis for API manufacture and address a perceived lack of regulatory clarity, several of the current authors published a science and risk based approach to ensuring patient safety and drug quality when using biocatalysis (Org. Process Res. Dev. 2012, 16, 1986−1993). Since this publication, consultation of multiple users and stakeholders in the biocatalysis community has expanded on key guidance and specific approaches, as well as providing real examples of regulatory review and approval in this article. Our ultimate goal as highlighted in this publication is to provide a clear path and knowledge base to enable a robust and sound science and risk-based approach for utilizing biocatalysis whenever appropriate for the manufacture of small molecule pharmaceuticals.
科研通智能强力驱动
Strongly Powered by AbleSci AI